Abstract
We re-assess the fasting plasma glucose (FPG) and 2-h post-load glucose (2HPG) in the diagnosis of both prediabetes and type 2 diabetes mellitus by developing a gold standard based on beta-cell function. The gold standard was developed in a cohort of 2,152 adult subjects without severe renal or liver dysfunction that also had a 2-h oral glucose tolerance test (OGTT) during the Third National Health and Nutrition Examination Survey. Beta-cell function was computed based on a composite of insulin secretion (determined based on the insulin and glucose responses to the OGTT) and the homeostasis model insulin resistance index. The X-tile program was used to generate the most appropriate categories of minor, moderate and severe impairment of beta-cell function based on the best discrimination of ln(insulin secretion). Subjects with a moderate or severe impairment in beta-cell function were used to define prediabetes and diabetes, respectively, and was the standard against which the FPG and 2HPG were evaluated. It is shown that the current definitions of diabetes by the FPG and 2HPG mirror those derived using impairment of beta-cell function as the gold standard. It is also shown that lowering the cutoff for the FPG does little to improve its use in the screening for prediabetes. A major finding is that the current 2HPG cutoff is inadequate and thus in need of revision to >6.7 mmol/L (>120 mg/dL) from 7.8 mmol/L (140 mg/dL) for the lower cutoff. The use of a model of beta-cell function and impairment of insulin secretion has thus put the utility of the FPG and 2HPG into perspective: We recommend that performing an OGTT be considered pivotal for accurate identification of subjects with impaired beta-cell function (and thus prediabetes) and a revision of the OGTT lower cutoff be considered based on the results of this study.
Similar content being viewed by others
References
R.A. DeFronzo, M.A. Abdul-Ghani, Preservation of beta-cell function: the key to diabetes prevention. J. Clin. Endocrinol. Metab. 96, 2354–2366 (2011)
M. Bergman, Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus. Endocrine 43, 504–513 (2013)
S. O’Rahilly, A. Hattersley, A. Vaag, H. Gray, Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet 344, 585–589 (1994)
A.J. Valleron, E. Eschwege, L. Papoz, G.E. Rosselin, Agreement and discrepancy in the evaluation of normal and diabetic oral glucose tolerance test. Diabetes 24, 585–593 (1975)
Anonymous, Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group, Diabetes. 28, 1039–1057 (1979)
Expert Committee on Diabetes Mellitus: Second Report. Technical report 646. 1980
R.J. Jarrett, H. Keen, Hyperglycaemia and diabetes mellitus. Lancet 2, 1009–1012 (1976)
H.A. Sayegh, R.J. Jarrett, Oral glucose-tolerance tests and the diagnosis of diabetes: results of a prospective study based on the Whitehall survey. Lancet 2, 431–433 (1979)
D.J. Pettitt, W.C. Knowler, J.R. Lisse, P.H. Bennett, Development of retinopathy and proteinuria in relation to plasma- glucose concentrations in Pima Indians. Lancet 2, 1050–1052 (1980)
M.B. Davidson, A.L. Peters, D.L. Schriger, An alternative approach to the diagnosis of diabetes with a review of the literature. Diabetes Care 18, 1065–1071 (1995)
Anonymous., Report of the expert committee on the diagnosis and classification of diabetes mellitus., Diabetes Care. 20, 1183–1197 (1997)
S. Genuth, K.G. Alberti, P. Bennett, J. Buse, R. Defronzo, R. Kahn, J. Kitzmiller, W.C. Knowler, H. Lebovitz, A. Lernmark, D. Nathan, J. Palmer, R. Rizza, C. Saudek, J. Shaw, M. Steffes, M. Stern, J. Tuomilehto, P. Zimmet, Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26, 3160–3167 (2003)
D.L. Schriger, B. Lorber, Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? Diabetes Care 27, 592–601 (2004)
M.B. Davidson, D.L. Schriger, A.L. Peters, B. Lorber, Revisiting the oral glucose tolerance test criterion for the diagnosis of diabetes. J. Gen. Intern. Med. 15, 551–555 (2000)
National Center for Health Statistics, Plan and operation of the third national health and nutrition examination survey, 1988–1994 (US Department of Health and Human Services, Hyattsville, 1994)
Diagnosis and classification of diabetes mellitus, Diabetes Care 37(Suppl 1), S81–S90 (2014)
J. Radziuk, Insulin sensitivity and its measurement: structural commonalities among the methods. J. Clin. Endocrinol. Metab. 85, 4426–4433 (2000)
K.J. Mather, A.E. Hunt, H.O. Steinberg et al., Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J. Clin. Endocrinol. Metab. 86, 5457–5464 (2001)
T.M. Wallace, J.C. Levy, D.R. Matthews, Use and abuse of HOMA modeling. Diabetes Care 27, 1487–1495 (2004)
J.C. Levy, D.R. Matthews, M.P. Hermans, Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21, 2191–2192 (1998)
M.J. Quon, Limitations of the fasting glucose to insulin ratio as an index of insulin sensitivity. J. Clin. Endocrinol. Metab. 86, 4615–4617 (2001)
A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, R.A. DeFronzo, Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 47, 31–39 (2004)
R.L. Camp, M. Dolled-Filhart, D.L. Rimm, X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin. Cancer Res. 10, 7252–7259 (2004)
R.A. Defronzo, D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, T.A. Buchanan, S.C. Clement, R.R. Henry, A.E. Kitabchi, S. Mudaliar, R.E. Ratner, F.B. Stentz, N. Musi, P.D. Reaven, A. Gastaldelli, Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Diabetes Care 36, 3607–3612 (2013)
R.A. Defronzo, D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, T.A. Buchanan, S.C. Clement, A. Gastaldelli, R.R. Henry, A.E. Kitabchi, S. Mudaliar, R.E. Ratner, F.B. Stentz, N. Musi, P.D. Reaven, Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 62, 3920–3926 (2013)
J. Armato, R.A. DeFronzo, M. Abdul-Ghani, R. Ruby, Successful treatment of prediabetes in clinical practice: targeting insulin resistance and beta-cell dysfunction. Endocr Pract 18, 342–350 (2012)
T. Higgins, HbA1c for screening and diagnosis of diabetes mellitus. Endocrine 43, 266–273 (2013)
T.N. Kim, M.S. Park, S.K. Lee, S.J. Yang, K.W. Lee, M. Nam, Y.S. Park, J.T. Woo, Y.S. Kim, S.H. Baik, Elevated A1C is associated with impaired early-phase insulin secretion rather than insulin resistance in Koreans at high risk for developing diabetes. Endocrine 42, 584–591 (2012)
M. Kanat, D. Winnier, L. Norton, N. Arar, C. Jenkinson, R.A. Defronzo, M.A. Abdul-Ghani, The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care 34, 1006–1010 (2011)
E. Uetani, Y. Tabara, M. Igase, T. Kido, N. Ochi, R. Takita, K. Kohara, T. Miki, Liver enzyme and adipocytokine profiles are synergistically associated with insulin resistance: the J-SHIPP study. J Atheroscler Thromb 19, 577–584 (2012)
T. Iwao, K. Sakai, E. Ando, Relative contribution of insulin secretion and sensitivity at different stages of glucose tolerance: non-obese versus obese Japanese subjects. Intern. Med. 53, 383–390 (2014)
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Doi, S.A.R., Ward, G.M. Examination of the fasting and 2-h plasma glucose in the light of impairment in beta-cell function: what does the epidemiological data tell us?. Endocrine 48, 170–178 (2015). https://doi.org/10.1007/s12020-014-0284-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0284-0